A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment
about
Renal effects of dapagliflozin in patients with type 2 diabetesDipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative reviewSodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectivesEfficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusAdvances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert ForumSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic AgentsInitiation and Intensification Strategies in Type 2 Diabetes Management: A Comparison of Basal Plus and Premix RegimensBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisEffect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal modelsThe role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.Sodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review and meta-analysis of randomized controlled trials.Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusComparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis.Current therapies and emerging drugs in the pipeline for type 2 diabetes.Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesRisk factors contributing to type 2 diabetes and recent advances in the treatment and prevention.SGLT-2 inhibitors in development for type 2 diabetes treatmentDapagliflozin for the treatment of type 2 diabetes.Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitusSystematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.The Sweet Pee model for Sglt2 mutationDapagliflozin efficacy and safety: a perspective review.Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.SGLT5 reabsorbs fructose in the kidney but its deficiency paradoxically exacerbates hepatic steatosis induced by fructoseDapagliflozinDapagliflozin for the treatment of type 2 diabetes: a review of the literatureDapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study.Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.Dapagliflozin in patients with type 2 diabetes mellitus.Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trialsDapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials.
P2860
Q24564811-8679F887-7CFE-4394-8783-B19566A66E77Q26767260-1F9FF963-CDC3-4479-9305-E3A8279AA9BEQ26767263-956BBF99-71F2-4A84-BA1C-878EB69DEBAFQ26782225-C6A1508F-0A41-43A9-9EB1-149380E342BDQ26784022-53840F03-BB56-4D07-B551-B01345E359FFQ28072765-EF7F8417-CF11-401E-BB66-22819250BAE1Q28074843-8DC0939C-89D4-446D-9C3B-B905B0CC1AF0Q28077688-5517B5A5-85D7-4C20-8AA9-B1485DACE256Q28553482-28F8BF51-33D2-4FC2-85D3-578EC6E14E09Q28732080-EEAFE9DD-7C90-4D75-B5AE-C3546EFC752EQ30663494-118DF2B0-902D-4EE7-AEFB-E1DA9AB4C347Q30833760-3B31086A-822C-45C6-BEAC-8AE834574E54Q32186373-1414CEE2-29B3-4A09-BFC5-81A04760940FQ33166813-7786BE92-92C4-406A-9CC5-528243634DCFQ33354192-A8AD1890-2EC7-4321-BCE1-B3D2C51753F5Q33760535-5E063F30-7130-4D70-B35B-BB79AA46AEB2Q33785128-3D34B71A-9110-49EC-90DE-819C2E2D5C71Q33871321-B66F617B-E75D-4D52-92F5-8E2E93628F0CQ33871397-F55F80E8-BB46-4C35-8645-3C09E220FF23Q33928941-70F1F837-2CFA-4951-8306-DB9BA4F7E889Q34153496-B98EC0B2-40E9-4393-B276-D6EAFEB9F436Q34161881-D03E5AE5-F647-482E-8936-A00B1024490FQ34198692-AD70F904-9015-464A-BD9E-F24BFD7E5BF9Q34201551-B863D96A-815C-420E-AC46-83BFBB951BF7Q34248505-DC74E177-969E-4206-8A67-E22C50B8CC78Q34262543-16F428A8-F4D2-4D59-B617-865EE637B864Q34407893-B1C62900-B700-45F7-A61B-FD79EDCBA2C8Q34453811-3856DB26-1430-4A54-8883-1191C3B9FD30Q34457273-E5596BC2-7AA2-423B-A0E6-856ED5EE7187Q34514280-6593F2DF-EB5A-454B-90A4-EF9FAB19DC37Q34593046-073F31E5-C94C-4814-9C22-54420A4D488EQ34602496-648FED0A-1AE2-4722-AFED-9F750B976641Q34613015-D8CFF68B-BD06-4C26-AFE6-99AEF5C7CCE4Q34710819-D3EA2C48-4202-46D0-ABEC-37FA05BCFAE1Q34726376-3F0305F9-2EB0-49F5-AF74-A1EC4331D4F3Q35014111-641DCD78-40F1-4DF3-9921-93AFF6A4974CQ35064363-F67FE3CF-B39E-43E9-8489-37A13F6F9176Q35068181-540BE5B5-B411-413A-AD6E-C5C22605B892Q35111555-57431754-BC82-4428-84E5-DF85AAFEDB42Q35141884-6EFD0CD3-1D6E-4009-80ED-B908EDF421EB
P2860
A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A study of dapagliflozin in pa ...... insulin-independent treatment
@en
A study of dapagliflozin in pa ...... insulin-independent treatment.
@nl
type
label
A study of dapagliflozin in pa ...... insulin-independent treatment
@en
A study of dapagliflozin in pa ...... insulin-independent treatment.
@nl
prefLabel
A study of dapagliflozin in pa ...... insulin-independent treatment
@en
A study of dapagliflozin in pa ...... insulin-independent treatment.
@nl
P2093
P2860
P921
P356
P1433
P1476
A study of dapagliflozin in pa ...... insulin-independent treatment
@en
P2093
Arnaud Bastien
Caroline T'joen
Fred T Fiedorek
James F List
Paul Norwood
P2860
P304
P356
10.2337/DC09-0517
P407
P50
P577
2009-06-15T00:00:00Z